Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 48Breast Neoplasms 8Neoplasms 4Leiomyoma 3Breast Neoplasms, Male 2Sexual Dysfunction, Physiological 1Prostate Adenocarcinoma 1Neoplasm Metastasis 1Myofibroma 1Breast Cancer Invasive 1Advanced Prostate Cancer 1Advanced Prostate Adenocarcinoma 1Adenocarcinoma 1

Interventions

Leucovorin 22Fluorouracil 22Gemcitabine 21Capecitabine 21Paclitaxel 20Docetaxel 20Irinotecan 15Carboplatin 15Radiosurgery 14Oxaliplatin 13Cisplatin 13Bevacizumab 13Zoledronic Acid 12pembrolizumab 11Radiotherapy 11Fulvestrant 11palbociclib 9Pemetrexed 9Drug Therapy 9130-nm albumin-bound paclitaxel 9Surgical Procedures, Operative 7Letrozole 7Ibandronic Acid 7abemaciclib 6Trastuzumab 6Prednisone 6Vinorelbine 5Folfox protocol 5Floxuridine 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasm Metastasis × Leuprolide × Clear all
NCT01442246 2024-09-19

Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

UNICANCER

Phase 3 Active not recruiting
700 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡